Shares of Insulet Corporation (PODD.O) experienced a notable uptick today, crossing above the 20-day simple moving average (SMA), signaling a potential shift in bullish momentum. This technical breakout comes on the heels of the company's optimistic financial outlook, projecting a robust revenue growth of approximately 20% CAGR from 2025 to 2028, primarily driven by the increasing adoption of its Omnipod product line and strategic geographic expansion.
Insulet's commitment to innovation is underscored by its plans to launch significant enhancements to the Omnipod 5 in 2026, followed by the introduction of Omnipod 6 in 2027, and a fully closed-loop system for type 2 diabetes management by 2028. These advancements are expected to enhance user experience and broaden market access, reinforcing Insulet's leadership in the automated insulin delivery sector.
The company’s strategic focus on operational efficiency and user-centered design further solidifies its position in the diabetes care market. As Insulet continues to leverage its strong financial foundation and unique product offerings, investors are optimistic about the future trajectory of PODD.O, reflected in today's positive price movement.
Wall Street analysts forecast PODD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PODD is 375.83 USD with a low forecast of 316.00 USD and a high forecast of 450.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
Wall Street analysts forecast PODD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PODD is 375.83 USD with a low forecast of 316.00 USD and a high forecast of 450.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 258.200
Low
316.00
Averages
375.83
High
450.00
Current: 258.200
Low
316.00
Averages
375.83
High
450.00
TD Cowen
Mathew Blackman
Buy
to
Hold
downgrade
$294
2026-01-26
New
Reason
TD Cowen
Mathew Blackman
Price Target
$294
AI Analysis
2026-01-26
New
downgrade
Buy
to
Hold
Reason
TD Cowen analyst Mathew Blackman downgraded Insulet to Hold from Buy with a $294 price target as the analyst took over coverage of the stock. Insulet has momentum, as O5 is capturing patients, driving top-tier growth, the analyst tells investors in a research note. The company wins on form factor/pharmacy, but the world is not static and the advantages compared to peers will likely narrow, the analyst adds. The firm also noted that while there are still growth opportunities and a visible pipeline, it sees modest upside ahead.
Goldman Sachs
David Roman
Buy
downgrade
$388 -> $365
2026-01-09
Reason
Goldman Sachs
David Roman
Price Target
$388 -> $365
2026-01-09
downgrade
Buy
Reason
Goldman Sachs analyst David Roman lowered the firm's price target on Insulet to $365 from $388 and keeps a Buy rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PODD
Unlock Now
Bernstein
Lee Hambright
Outperform
downgrade
$410 -> $380
2026-01-09
Reason
Bernstein
Lee Hambright
Price Target
$410 -> $380
2026-01-09
downgrade
Outperform
Reason
Bernstein analyst Lee Hambright lowered the firm's price target on Insulet to $380 from $410 and keeps an Outperform rating on the shares. After a low point in September 2025, U.S. healthcare stocks have begun to perform better over the past several months, the firm notes. As the market gets more clarity on many of the macro / policy uncertainties that weighed on healthcare stocks during the course of 2025, Bernstein anticipates better days ahead for healthcare stocks in 2026.
Truist
Buy
downgrade
$412 -> $390
2025-12-18
Reason
Truist
Price Target
$412 -> $390
2025-12-18
downgrade
Buy
Reason
Truist lowered the firm's price target on Insulet to $390 from $412 and keeps a Buy rating on the shares as part of a broader research note previewing 2026 for MedTech. The firm is more positive on the industry heading into next year given a more attractive relative sector valuation, though it also sees the possibility of it being a "source" vs. a destination of new healthcare investment flows, the analyst tells investors in a research note. Truist adds it prefers names with 2026 catalysts fueling durable revenue acceleration or out-of-favor near-term narratives.
About PODD
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
